Research strategies of small molecules as chemotherapeutics to overcome multiple myeloma resistance
Eur J Med Chem. 2024 Apr 20;271:116435. doi: 10.1016/j.ejmech.2024.116435. Online ahead of print.ABSTRACTMultiple myeloma (MM), a cancer of plasma cells, is the second most common hematological malignancy which is characterized by aberrant plasma cells infiltration in the bone marrow and complex heterogeneous cytogenetic abnormalities. Over the past two decades, novel treatment strategies such as proteasome inhibitors, immunomodulators, and monoclonal antibodies have significantly improved the relative survival rate of MM patients. However, the development of drug resistance results in the majority of MM patients suffering from relapse, limited treatment options and uncontrolled disease progression after relapse. There are urgent needs to develop and explore novel MM treatment strategies to overcome drug resistance and improve efficacy. Here, we review the recent small molecule therapeutic strategies for MM, and introduce potential new targets and corresponding modulators in detail. In addition, this paper also summarizes the progress of multi-target inhibitor therapy and protein degradation technology in the treatment of MM.PMID:38648728 | DOI:10.1016/j.ejmech.2024.116435
Source: European Journal of Medicinal Chemistry - Category: Chemistry Authors: Jin Yang Yan-Cheng Yu Zi-Xuan Wang Qing-Qing Li Ning Ding Xue-Jiao Leng Jiao Cai Meng-Yuan Zhang Jing-Jing Wang Yun Zhou Tian-Hua Wei Xin Xue Wei-Chen Dai Shan-Liang Sun Ye Yang Nian-Guang Li Zhi-Hao Shi Source Type: research